Cardiol Therapeutics Inc. Class A Common Shares (CRDL) Dividend History

Company News

• 5 Small Drug Stocks to Buy From a Recovering Industry

  Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

  Zacks Investment Research

  Featured Companies: ACRV AQST BVS HRTX
• Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In

  Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says. Influence Of DEA Rescheduling Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he stated, highlighting the potential for new pharmaceutical applications and a diversification of medical cannabis products. Bingham notes that the rescheduling will be a game-changer for research, allowing scientists to pursue careers studying cannabinoids without risking their careers. "For the last 50 years, studying cannabinoids was a career ender for young scientists. Now, they will be able to pursue it and come up with fascinating discoveries."  Economic And Operational Impacts The rescheduling is likely to alleviate financial pressures on cannabis businesses, notably by eliminating certain tax burdens, which Bingham says will "inject much more cash and capital into the industry." This financial liberation is expected to accelerate research and development, particularly in medical cannabis, potentially attracting substantial investment from healthcare and pharmaceutical companies. He also anticipates ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: ABBV CRBP HRMY JAZZ PFE
• Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?

  Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.

  Zacks Investment Research

  Featured Companies: AUPH CORT
• Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock

  Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.

  Zacks Investment Research

  Featured Companies: AUPH CORT
• Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

  Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer. Neptune Wellness Solutions Inc. (NASDAQ: NEPT) shares rose 28.5% to $5.03 in pre-market trading after falling 11% on Wednesday. Neptune Wellness announced intention to spinout Sprout Organics pursuant to the Morgan Stanley agreed to transaction. Murphy Canyon Acquisition Corp. (NASDAQ: MURF) shares rose 32.4% to $17.00 in pre-market trading. Murphy Canyon Acquisition reported stockholder approval of the proposed combination with Conduit Pharmaceuticals. TradeUP Acquisition Corp. (NASDAQ: UPTD) shares jumped 24.2% to $15.22 in pre-market trading after surging 26% on Wednesday. The company announced an extension for its initial business combination deadline, depositing an aggregate of $37,432.70 into its trust account. Alliance Entertainment Holding Corporation (NASDAQ: AENT) shares gained 19.8% to $1.27 in pre-market trading after falling ...

  Benzinga

  Featured Companies: AEHL AENT ARBB ELUT FTEL HSCS KZR RNAZ